Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update • Advanced OTX-2002 in MYCHELANGELO™ I trial; initial cohorts demonstrated encouraging disease control rate in late-stage HCC patients • Established a research collaboration with Novo Nordisk to develop an epigenomic controller for obesity, expanding the pipeline into the cardiometabolic space • Announced strategic prioritization to focus resources on potential near-term value drivers, support long-t ...